- Home
- ENX vs VTYX Comparison
ENX vs VTYX Comparison
Compare ENX & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENX
- VTYX
- Stock Information
- Founded
- ENX 2002
- VTYX 2018
- Country
- ENX United States
- VTYX United States
- Employees
- ENX N/A
- VTYX N/A
- Industry
- ENX Finance/Investors Services
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- ENX Finance
- VTYX Health Care
- Exchange
- ENX Nasdaq
- VTYX Nasdaq
- Market Cap
- ENX 169.0M
- VTYX 154.9M
- IPO Year
- ENX N/A
- VTYX 2021
- Fundamental
- Price
- ENX $9.39
- VTYX $2.74
- Analyst Decision
- ENX
- VTYX Buy
- Analyst Count
- ENX 0
- VTYX 2
- Target Price
- ENX N/A
- VTYX $9.00
- AVG Volume (30 Days)
- ENX 25.4K
- VTYX 760.1K
- Earning Date
- ENX 01-01-0001
- VTYX 08-07-2025
- Dividend Yield
- ENX 3.94%
- VTYX N/A
- EPS Growth
- ENX N/A
- VTYX N/A
- EPS
- ENX 0.16
- VTYX N/A
- Revenue
- ENX N/A
- VTYX N/A
- Revenue This Year
- ENX N/A
- VTYX N/A
- Revenue Next Year
- ENX N/A
- VTYX N/A
- P/E Ratio
- ENX $61.00
- VTYX N/A
- Revenue Growth
- ENX N/A
- VTYX N/A
- 52 Week Low
- ENX $7.84
- VTYX $0.78
- 52 Week High
- ENX $10.07
- VTYX $3.39
- Technical
- Relative Strength Index (RSI)
- ENX 57.20
- VTYX 51.07
- Support Level
- ENX $9.28
- VTYX $2.38
- Resistance Level
- ENX $9.48
- VTYX $3.05
- Average True Range (ATR)
- ENX 0.11
- VTYX 0.22
- MACD
- ENX 0.00
- VTYX -0.02
- Stochastic Oscillator
- ENX 22.77
- VTYX 55.15
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.